Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
A.L. Olson
Observed name:
A. Olson
Institution:
Boehringer Ingelheim (United States)
Observed institution:
Boehringer Ingelheim (United States)
OpenAlex ID:
A5057870045
Real-World Medication Adherence Trajectories of Nintedanib Among Idiopathic Pulmonary Fibrosis Patients
2022
·
A.J. Epstein
, M. Nili
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
1
Potentially Avoidable Healthcare Costs Associated With Delayed Diagnosis of Fibrotic Interstitial Lung Disease (ILD)
2024
·
S. Shetty
, S. Shah
, et al.
·
American Journal of Respiratory and Critical Care Medicine
Care Patterns of Patients With Connective Tissue Disease-related Interstitial Lung Disease
2024
·
J. Yang
, M. Head
, et al.
·
American Journal of Respiratory and Critical Care Medicine
Development and Validation of Case-finding Algorithms for Use in Secondary Electronic Health Databases to Identify Patients With Fibrotic Interstitial Lung Disease
2023
·
P. Pimple
, A. Berger
, et al.
·
American Journal of Respiratory and Critical Care Medicine
Association Between Nintedanib Adherence Trajectories and Healthcare Use Among Idiopathic Pulmonary Fibrosis Patients
2023
·
M. Nili
, A.J. Epstein
, et al.
·
American Journal of Respiratory and Critical Care Medicine
Deep Learning Improves Sensitivity of UIP Classification on CT
2022
·
S.M. Humphries
, D. Thieke
, et al.
·
American Journal of Respiratory and Critical Care Medicine
Incidence of Progressive Phenotype in Fibrosing Interstitial Lung Disease (PF-ILD) in a Tertiary Healthcare Center
2022
·
M.G. Macmurdo
, X. Ji
, et al.
·
American Journal of Respiratory and Critical Care Medicine
Show more works
View as search
Works count:
7
Citation count:
1
H-index:
1
I10-index:
Year
Topic
Type
